A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder

Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Fluoxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 11 Dec 2013 Planned End Date changed from 1 Sep 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top